Bristol Myers Squibb reports successful trial for myeloma treatment

Bristol Myers Squibb (BMS) is making significant strides in the fight against multiple myeloma, a complex blood cancer.

Central to this progress is ZENBEXUS™ (iberdomide), a novel CELMoD agent.

In the Phase 3 EXCALIBER-RRMM trial, patients using a regimen containing ZENBEXUS showed much better clinical outcomes compared to standard treatments.

The U.S.

FDA recently granted accelerated approval for this regimen, marking a major milestone for patients who have already undergone prior therapy.

Beyond small-molecule drugs like ZENBEXUS and mezigdomide, BMS is advancing its cell therapy pipeline.

The Phase 2 QUINTESSENTIAL trial revealed that its investigational CAR T-cell therapy, arlo-cel, achieved strong response rates in patients who were previously resistant to other treatments.

By targeting GPRC5D, arlo-cel offers a new path for those who have exhausted existing options.

Through both CELMoD platforms and sophisticated CAR T technology, BMS is successfully refreshing its hematology portfolio to tackle treatment resistance.